Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

115.66 +0.16 (+0.13%)
Streaming Delayed Price Updated: 1:40 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
Horizon Therapeutics' Shares Tumble On Q2 Miss, Trimmed FY22 Outlook
Via Benzinga
Analyst Ratings for Horizon Therapeutics
Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter: 
Via Benzinga
Dow Jumps 350 Points; Crude Oil Drops Over 2%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 350 points on Wednesday. 
Via Benzinga
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Analyst Ratings for Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
4 Analysts Have This to Say About Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Horizon Therapeutics: Q2 Earnings Insights
  Horizon Therapeutics (NASDAQ:HZNP) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Horizon Therapeutics Receives FDA Approval For Uncontrolled Gout Candidate
The U.S. Food and Drug Administration (FDA) has approved Horizon Therapeutics’ (NASDAQ: HZNP) supplemental Biologics License Application (sBLA) for expanding the labeling to include KRYSTEXXA... 
Via Benzinga
Horizon Therapeutics: Q1 Earnings Insights
Horizon Therapeutics (NASDAQ:HZNP) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million,... 
Via Benzinga
Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata
Horizon Therapeutics plc (NASDAQ: HZNP) enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab (HZN-7734) to treat people with moderate-to-severe... 
Via Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Following Friday's Sell-Off
Pre-open movers 
Via Benzinga
Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?
If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Eton Pharmaceuticals Names James Gruber Finance Chief
Eton Pharmaceuticals Inc (NASDAQ: ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring.... 
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
Executives Sell More Than $262M Of 5 Stocks
Although gold futures traded higher on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.